Fludarabine based therapies had been the backbone of the CLL treatment but in modern era, therapy heavily depends on cytogenetic analysis and in TP-53 mutated cases bruton tyrosine kinase inhibitors like ibrutinib and idelalisib and bcl-2 inhibitor venetoclax are now integrated as first line treatment of CLL [3], [4]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.